Click the “Start Activity” button to indicate you have reviewed the CME information for this activity.
Faculty
Parameswaran Hari, MD, MRCP, MS
Armand Quick-William Stapp Professor of Hematology
Interim Chief Hematology and Oncology
Medical College of Wisconsin
Milwaukee, WI
Luciano J. Costa, MD, PhD
Associate Professor
Department of Medicine and Bone Marrow
Transplantation and Cell Therapy Program
University of Alabama, Birmingham
Birmingham, AL
Release date: June 30, 2018
Expiration date: June 30, 2019
Program Overview
The goal of this educational program is to improve the treatment of patients with multiple myeloma (MM) and non-hodgkin lymphoma (NHL) through the dissemination of information about stem cell transplantation and mobilization for autologous hematopoietic cell transplantation. The data for stem cell transplantation in MM is rapidly changing. The techniques of mobilization are still evolving. There is considerable debate regarding the timing and number of transplants for MM and the indications for transplant in NHL. The optimal use of transplant in the disease course and appropriate mobilization could drastically change the treatment of MM and NHL. This program serves as a medium to give physicians a chance to recognize these changes.
Learning Objectives
The following items are the learning objectives in CME format for this program. Upon completion of this program, participants will be able to:
- Identify existing and emerging strategies for optimizing stem cell transplantation in MM and NHL
- Evaluate current data on stem cell mobilization in patients with MM and Hodgkin’s disease
- Determine the factors that affect and optimize the efficacy of stem cell mobilization
Target Audience
This activity has been developed and is intended for transplant specialists, oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with hematologic malignancies.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and Carden Jennings Publishing. The Medical College of Wisconsin is accredited with commendation by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement
The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
This enduring material is approved for one year from the date of original release, June 20, 2018 to June 20, 2019.
Off-Label/Investigational Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Medical College of Wisconsin, or Carden Jennings Publishing.
Before prescribing any medication, physicians should consult primary references and full prescribing information. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants should appraise the information presented critically, and are encouraged to consult appropriate resources for any product or device mentioned in this activity.
CJP Medical Communications Disclosure
The employees of CJP Medical Communications have no financial relationships to disclose.
Faculty Disclosures
Consistent with the current Accreditation Council for Continuing Medical Education policy, the CME Provider must be able to show that everyone who is in a position to control the content of an individual educational activity has disclosed all relevant financial relationships. The CME Provider has a mechanism in place to identify and resolve any conflicts of interest discovered in the disclosure process. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant:
Parameswaran Hari, MD, MRCP, MS discloses that received honoraria from Celgene, Takeda, Janssen, Sanofi, and Spectrum.
Luciano J. Costa, MD, PhD discloses that received honoraria from Amgen, Celgene, and Sanofi.
John R. Wingard, MD, has no relevant financial relationships to disclose.
Hemant Murthy, MD, has no relevant financial relationships to disclose.
Jack Hsu, MD, has no relevant financial relationships to disclose.
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity.